NCT04029766已完成1 期
A Phase 1 Study to Investigate a Single Bolus Dose Followed With a 30 Minute Constant Infusion of HSK3486 on the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of HSK3486 in Healthy Male Subjects.
Sichuan Haisco Pharmaceutical Group Co., Ltd0 个研究点目标入组 13 人开始时间: 2015年11月10日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 13
- 主要终点
- Safety by measurement of Adverse Events
研究概览
简要总结
This study was a single center, open-label, single dose escalation study in healthy male subjects to investigate a bolus dose followed by a 30 minute constant infusion of HSK3486 over two cohorts.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 49 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Male, aged 18 - 49 years (inclusive);
- •Be in general good health without clinically significant medical history;
- •American Society of Anesthesiologists (ASA) Physical Status Classification of I or II;
- •Body Mass Index (BMI) between 18 and 30 kg/m2 (inclusive);
- •Negative screen for drugs of abuse, alcohol, hepatitis B surface antigen (HBs-Ag), hepatitis C (HCVAb) and Human Immunodeficiency Virus (HIV) at Screening; and drugs of abuse, alcohol pre dose on Day -1
- •Normal or non-clinically significant findings on a physical examination, 12-lead electrocardiogram (ECG) and vital signs (respiration rate between 12 and 20 breaths per minute, blood pressure (BP) between 100-140/60-90 mmHg, heart rate between 50-99 beats per minute, temperature between 35.8°C and 37.5°C and pulse oximetry values > 95% on room air.);
- •Clinical laboratory values within the normal limits as defined by the clinical laboratory, unless the Investigator decided that out-of-range values were not clinically significant;
- •Ability to provide written informed consent;
- •Willing and able to follow study instructions and likely to complete all study requirements;
- •Suitable venous and arterial access.
排除标准
- •History of allergy or sensitivity to: propofol, components of Fresofol 1% MCT/LCT propofol, or HSK3486 (excipients soy bean oil, glycerine, triglycerides, purified egg phospholipids, sodium oleate and sodium hydroxide), or plain lignocaine;
- •History of clinically significant problems with general anesthesia;
- •Current smoker, or a history of regular (more than weekly) use of tobacco- or nicotine-containing products within 2 months prior to Screening;
- •History of excessive alcohol intake (more than four standard drinks daily, on average) or use of recreational drugs within the last 3 months;
- •Use of prescription or over the counter medications within 7 days of Investigational Product administration, with the exception of contraceptive medications, paracetamol, oral non-steroidal antiinflammatory agents, topical over the counter preparations and routine vitamins (if they do not exceed an intake of 20 to 600 times the recommended daily dose), unless agreed as non-clinically relevant by the Principal Investigator and Sponsor;
- •Standard donation of blood within 30 days of the study;
- •Donation of plasma or participation in a plasmapheresis program within 7 days preceding this study;
- •Receipt of any investigational study drug within 30 days prior to Screening;
- •Unable to fast for the 6 hours prior to Investigational Product administration;
- •Clinically significant (as judged by the Investigator) presence of acute illness (e.g. gastrointestinal illness, infection such as influenza, upper respiratory tract infection) at admission to the clinical study unit;
- •Anticipated need for surgery or hospitalization during the study;
- •Anatomical abnormality that would potentially interfere with airway management under unconscious sedation or anesthesia;
- •History of posture-related gastric reflux more than twice weekly;
- •History of seizures or epilepsy ;
- •History of ischaemic heart disease;
- •History of brady- or tachy-dysrhythmias requiring medical care;
- •History of asthma, with bronchospasm requiring treatment in the last 3 months;
- •Any condition, which in the Investigator's opinion, put the subject at significant risk, could confound the study results or may interfere significantly with the subject's participation in the study.
研究组 & 干预措施
HSK3486
Experimental
0.288 mg/kg bolus (1 min)+ 1 mg/kg/h constant infusion (30 min) or 0.540 mg/kg bolus (1 min)+ 2 mg/kg/h constant infusion (30 min)
干预措施: HSK3486 (Drug)
结局指标
主要结局
Safety by measurement of Adverse Events
时间窗: First dose of study drug on day 1
次要结局
- Modified observer's assessment of alertness/sedation（MOAA/S）(From first dose of study drug until fully alert on day 1)
- Bispectral index （BIS）(From first dose of study drug until fully alert on day 1)
- Area Under the Curve (AUC0-30min, AUC0-1h, AUC0-last, and AUC0-inf)(From the start of administration to 48 hours after administration)
- Peak concentration (Cmax)(From the start of administration to 48 hours after administration)
- Terminal elimination half life (t1/2z) and mean residence time (MRT)(From the start of administration to 48 hours after administration)
- Total clearance (CL)(From the start of administration to 48 hours after administration)
- Mean residence time (MRT)(From the start of administration to 48 hours after administration)
- Median effective dose (ED50)(From first dose of study drug until fully alert on day 1)
- Time to plasma peak concentration(Tmax)(From the start of administration to 48 hours after administration)
研究者
相似试验
已完成
1 期
Safety and Tolerability of GX-G6 in Healthy Male SubjectsDiabetes MellitusNCT03651466Genexine, Inc.48
Unknown
1 期
Randomized, Double Blinded, Placebo Controlled, Single Dose Escalation Study of 608 in Healthy SubjectsModerate to Severe Plaque PsoriasisNCT04367441Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.62
Unknown
1 期
A Study of SSS17 in Healthy SubjectsAnemia in Chronic Kidney DiseasesNCT04317833Shenyang Sunshine Pharmaceutical Co., LTD.65
终止
1 期
A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid LeukemiaAcute Myeloid LeukaemiaNCT05712278Sanofi7
已完成
1 期
A First-in-Human Study With XAB05 in Healthy SubjectsInfection, BacterialNCT05307406Xenothera SAS25